Skip to content
Chandler PRP Clarity
An East Valley measurement desk

Chandler PRP Clarity

Straight answers to common PRP questions

Which PRP questions matter before treatment? Ask about likely relief, full cost, side effects and time away from normal activity.

The answer changes with the location of the ache and the exam. PRP may be discussed at QC Kinetix; it is a blood layer with extra clot-forming platelets saved by machine.

You can ask for plain answers before choosing care. The office should explain what happens, what it costs and when to call.

PRP doesn't have the same result for every person. A clear answer should name the aching area and the reason for using it.

What is PRP?

PRP means platelet-rich plasma. Platelets are small pieces in blood; they gather at a cut and send signals that begin repair. A trained medical provider draws blood, spins it and saves the layer with more platelets. That layer is then placed near the aching joint or strained tendon.

Does PRP work for joint soreness?

PRP may ease soreness for some people, but the location and cause matter. Knee research is mixed, so help isn't certain. A knee study can't answer a shoulder or tendon question. Ask what the research found for your aching area.

What does PRP cost?

PRP is commonly paid out of pocket. Ask for a written quote covering the proposed visits and follow-up care. The quote should also state any fee if care stops later. Don't pay until every charge is clear.

How long does recovery take?

Soreness, swelling and stiffness are often brief after PRP. Recovery still differs with the body part and care given. Ask the doctor or nurse how much activity is safe at home. Get an office number and clear reasons to call.

What side effects need quick care?

Fever with marked heat and swelling around a joint needs urgent care. Spreading redness, drainage or calf swelling also needs quick attention. Get help for new weakness or lost use after a pop. Don't wait for the soreness to settle on its own.

What happens at the first visit?

A doctor, nurse or other trained medical provider asks how the soreness began. The visit includes checks of the joint, medicines and prior care. Ask why the proposed treatment suits the exam. Also ask how progress will be checked on a daily task that has become hard.

Sources

  1. The DEPA classification was built because platelet and leukocyte counts alone do not describe an injection. Applied retrospectively to 20 published PRP preparations, the dose of injected platelets ranged from 0.21 billion to 5.43 billion - a 25-fold spread. No device recovered more than 90% of the platelets in the blood drawn, and most preparations were contaminated with red blood cells: only three of the devices reached a purity score corresponding to more than 90% platelets relative to red cells and leukocytes.

    Magalon J, Chateau AL, Bertrand B, et al. — DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport & Exercise Medicine, 2016. DOI: 10.1136/bmjsem-2015-000060.

  2. A prospective cohort of 253 patients with KL 1-3 knee OA treated with three injections of 5 mL of autologous PRP found that platelet concentration positively correlated with clinical outcome. KOOS Pain improved more with higher platelet concentration at 2 months (P=.036), 6 months (P=.009) and 12 months (P=.014), with the same trend across other KOOS subscales and IKDC. The failure rate was 15.0% in the low-platelet group versus 3.3% in both the medium- and high-platelet groups, with no difference in adverse events.

    Boffa A, De Marziani L, Andriolo L, et al. — Influence of Platelet Concentration on the Clinical Outcome of Platelet-Rich Plasma Injections in Knee Osteoarthritis. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465241283463.

  3. A systematic review of 29 randomized trials of PRP for knee OA that reported a platelet count, concentration or dose found that the 28 treatment arms with statistically significant positive outcomes at 6 months had a mean platelet dose of 5,500 (+/-474) x 10^6, while the three arms without a positive difference averaged 2,302 (+/-437) x 10^6 (P<.01). The same separation held at 12 months: 5,464 versus 2,253 x 10^6 (P<.05).

    Berrigan WA, Bailowitz Z, Park A, et al. — A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review. Arthroscopy, 2025. DOI: 10.1016/j.arthro.2024.03.018.

  4. A systematic review and meta-analysis of platelet dosage across musculoskeletal conditions identified a potential dose-response relationship in knee osteoarthritis, with an apparent threshold above 10 billion platelets for favourable clinical outcomes, and the effect more pronounced for function than for pain. For conditions other than knee OA the authors found the literature too unclear to identify an optimal dose.

    Berrigan W, Tao F, Kopcow J, et al. — The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Current Reviews in Musculoskeletal Medicine, 2024. DOI: 10.1007/s12178-024-09922-x.

  5. A systematic review that screened 876 studies and extracted standardised data from 33 commercially available PRP systems and protocols found that final product concentrations of platelets, white cells and growth factors varied widely between systems, as did the preparation protocols themselves. Platelet concentration correlated directly with the volume of blood drawn and with the centrifugal force of the device. The authors called the heterogeneity between separation systems something that 'must be resolved for proper study of this promising treatment'.

    Fadadu PP, Mazzola AJ, Hunter CW, et al. — Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. Regional Anesthesia and Pain Medicine, 2019. DOI: 10.1136/rapm-2018-100356.

  6. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

    U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

  7. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

    Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

A visit can sort out the cause

The Chandler office can review the sore joint, medicines and earlier care. There is no charge for the consultation.

Bring one activity that soreness now limits. Call (602) 837-PAIN or visit 1100 S. Dobson Rd., Suite 210.

Book a free consultation